EWTX · Edgewise Therapeutics, Inc. · Executive Compensation
$40.30
-1.10 (-2.66%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$4.27B
Shares
108.60M
Volume · Oct 5
1.63M
Avg daily vol (3M)
1.35M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Martin | Class I director | Appointed | 2025-11-20 |
| Michael Carruthers | Chief Financial Officer | Retired | 2025-11-10 |
| Michael Nofi | Chief Financial Officer | Appointed | 2025-11-10 |
| Behrad Derakhshan | Chief Operating Officer | Appointed | 2025-01-22 |
| Arlene Morris | Class I director | Appointed | 2024-05-07 |
| Kenneth Harrison, Ph.D. | Board | Resigned | 2023-06-22 |
| Dr. Jonathan Fox | Class III director | Appointed | 2023-03-06 |